Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lucian Radu Chirieac, M.D.

Co-Author

This page shows the publications co-authored by Lucian Chirieac and Beow Yeap.
Connection Strength

1.020
  1. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013 Dec 20; 31(36):4544-9.
    View in: PubMed
    Score: 0.139
  2. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010 Feb 01; 116(3):659-69.
    View in: PubMed
    Score: 0.107
  3. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009 Nov 01; 69(21):8341-8.
    View in: PubMed
    Score: 0.105
  4. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
    View in: PubMed
    Score: 0.104
  5. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-1986.
    View in: PubMed
    Score: 0.103
  6. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008 Oct 15; 113(8):2129-38.
    View in: PubMed
    Score: 0.098
  7. Association of RERG Expression with Female Survival Advantage in Malignant Pleural Mesothelioma. Cancers (Basel). 2021 Feb 02; 13(3).
    View in: PubMed
    Score: 0.057
  8. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol. 2021 01; 253(1):68-79.
    View in: PubMed
    Score: 0.056
  9. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res. 2016 Jan 15; 76(2):319-28.
    View in: PubMed
    Score: 0.040
  10. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res. 2013 May 01; 19(9):2493-502.
    View in: PubMed
    Score: 0.033
  11. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 2010 Aug; 34(8):1193-8.
    View in: PubMed
    Score: 0.028
  12. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010 Jul; 177(1):415-23.
    View in: PubMed
    Score: 0.027
  13. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer. 2010 Mar 15; 116(6):1510-7.
    View in: PubMed
    Score: 0.027
  14. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
    View in: PubMed
    Score: 0.026
  15. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):11021.
    View in: PubMed
    Score: 0.026
  16. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem. 2007 Aug; 82(4-5):189-97.
    View in: PubMed
    Score: 0.023
  17. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006 Apr 01; 24(10):1561-7.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.